Agenus (AGEN) Non-Current Debt (2010 - 2025)

Agenus (AGEN) posted quarterly Non-Current Debt of $23.6 million for Q3 2025, up 1.94% quarter-over-quarter from $23.2 million in Q2 2025.

Agenus (AGEN) Non-Current Debt (2010 - 2025) Analysis & Trends

Agenus' Non-Current Debt history runs 16 years deep, the most recent figure standing at $23.6 million for Q3 2025.

In Q3 2025, Non-Current Debt changed N/A year-over-year to $23.6 million; the TTM figure through Sep 2025 stood at $23.6 million (changed N/A YoY), while the FY2024 annual figure was $30.5 million, up 138.67% from the prior year.
Non-Current Debt for Q3 2025 stood at $23.6 million, up from $23.2 million in the prior quarter.
The five-year high for Non-Current Debt was $32.8 million in Q1 2025, with the low at $12.6 million in Q4 2022.
The 5-year median for Non-Current Debt is $12.8 million (2021), against an average of $18.2 million.
The sharpest annual moves came in 2021 and 2024: Non-Current Debt tumbled 32.15% in 2021, then soared 138.67% in 2024.
Agenus' Non-Current Debt stood at $12.8 million in 2021, then declined by 1.86% to $12.6 million in 2022, then gained by 1.46% to $12.8 million in 2023, then jumped by 138.67% to $30.5 million in 2024, then decreased by 22.56% to $23.6 million in 2025.
Business Quant data shows AGEN's Non-Current Debt at $23.6 million in Q3 2025, $23.2 million in Q2 2025, and $32.8 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Agenus	311.95 Mn	286.43 Mn	34.52 Mn	-

Download Data